Repros Therapeutics

Repros Therapeutics — Investor Presentation (December 2011)

17 slides from Repros Therapeutics's investor presentation, Dec 1, 2011

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements that are not historical facts contained in this release are forward - looking statements that involve risks and uncertainties, including Repros ' ability to have the partial hold on Proellex ® lifted and to determine a safe and effective dose for Proellex ®, raise ne

  3. Slide 3: Product Development Highlights

    Product Development Highlights • Focused strategy: small molecule therapeutics for endocrine and reproductive disorders • Two late stage clinical programs with total $5B+ sales potential • Proellex : non - invasive treatment for female reproductive disorders ($5B+ market) – Chronic relief of uterine

  4. Slide 4: Fibroids and Endometriosis Major Unmet Female Disorders

    Fibroids and Endometriosis Major Unmet Female Disorders • Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus Most common tumor of the female reproductive tract Heavy bleeding / anemia Abdominal pressure / pain / urinary frequency • Affect 20 - 77% of women age 35 – 55 • 600,00

  5. Slide 5: Proellex Development Status

    Proellex Development Status • Complete Phase 2 Low Dose Trial by Year End – Hold Type B meeting with FDA Q2 - 12 – Commence Phase 3 Study for endometriosis in 2012 • IND for Phase 2 Vaginal Delivery Product for Treatment of Uterine Fibroids Submitted – Expect IND Effective by Year End – Expect Type

  6. Slide 6: Can Low Dose Proellex Work?

    Can Low Dose Proellex Work? 0 20 40 60 80 100 120 140 160 Baseline 1 Month 2 Month 3 Month PBAC Score Phase 2 UF Study Placebo 12.5 mg 0 5 10 15 20 25 30 35 40 45 Placebo 12.5 mg Normal UFSQOL Phase 2 UF Study Symptom Severity 0 10 20 30 40 50 60 70 80 90 100 Placebo Proellex BBSS ( Dysmenorrhea ) P

  7. Slide 7: So Why Pursue Vaginal Delivery?

    So Why Pursue Vaginal Delivery? 0 10 20 30 40 50 60 70 80 90 100 Baseline 3 month treatement @ 25mg 4 month treatment @ 50mg % of Fibroid Volume Control 50 mg Oral 12.5 mg Vaginal 0 500 1000 1500 2000 1 mg 3 mg 6 mg 9 mg 12.5 mg 25 mg 50 mg Proellex + Metabolite (ng/ml) Maximum Concentration in Seru

  8. Slide 8: Proellex Summary

    Proellex Summary • Highly Effective Treatment for Both Fibroids and Endometriosis • Large Unaddressed Markets • Growing Patent Estate • Moving to Phase 3

  9. Slide 9: Testosterone Market Continues to Grow

    Testosterone Market Continues to Grow 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 1998 2000 2002 2004 2006 2008 2010 2012 $ millions • Current worldwide sales >$1.6B • 25% compound annual growth • US accounts for 75% of global sales • Major pharmaceutical companies have moved to capture US oppor

  10. Slide 10: Causes of Low Testosterone

    Causes of Low Testosterone It’s really obesity Primary - Gonadal Low T & Elevated LH • Congenital - Klinefelter’s and variants • Mumps and other viruses • Trauma Secondary Central Low T & Low LH • Pituitary - Hypothalamic • Aging ? • Lupron • Diabetes Mellitus Courtesy of Richard F. Spark MD, FACE B

  11. Slide 11: European Male Aging Study

    European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 70 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng / dL LH: 5.2 U/L Age: 59.4 (10.4) BMI: 30.8 (

  12. Slide 12: Traditional HRT May Contribute to Male Infertility

    Traditional HRT May C ontribute to Male I nfertility Testes Hypothalamus / Pituitary Axis • Endogenous estrogen provides n egative feedback • Exogenous testosterone results in decrease or shut down of pituitary secretions • Testicular function decreases or shuts down Leydig Cell Activity Suppressed

  13. Slide 13: Exogenous T Castrates at the Level of the Pituitary

    Exogenous T Castrates at the Level of the Pituitary 0 5 10 15 20 25 30 % of Men with Undetectable FSH 0 5 10 15 20 25 30 35 % of Men with Undetectable LH

  14. Slide 14: Mean Morning TT Over Time (ZA-204)

    0 100 200 300 400 500 600 700 Morning TT (ng/dL) Fig. 14: Mean Morning TT Over Time (ZA - 204) 6.25mg Androxal 12.5mg Androxal 25mg Androxal Androgel Screening Baseline Week 2 Week 4 Week 6 Last Dosing Day One Week Follow - up ZA - 204 6 Week Study with 24 hour TT assessment at Baseline and Week 6

  15. Slide 15: Androxal Profiles Favorably vs. Current Gels/Creams

    Androxal Profiles Favorably vs. Current Gels/Creams P P P P P P P P P T Gels/Creams Androxal Administration Applied to Skin Oral Controlled Substance Yes No Infertility Risk Yes No Shrinks Testes Yes No Sexual Partner Risk Yes* No Unpredictable Peak Testosterone Yes No Potential for Abuse/Super-Norm

  16. Slide 16: Androxal Status

    Androxal Status • Type C Meeting with DRUP & DMEP this Year • Poised to Move to Phase 3 • Highly Differentiated Product – Potential Metabolic Benefits • Existing & Pending Patents to mid 2020’s

  17. Slide 17: Repros Summary

    Repros Summary Two Highly Differentiated and Patent Protected Products Addressing Large Markets Poised to Move to Phase 3

Repros Therapeutics — Investor Presentation (December 2011) on 6ix